Pancreatic Cancer Research

ResearcherGlasgow Royal InfirmaryActive in the last 2 years

Nigel Balfour Jamieson

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-9552-4725; OpenAlex author ID A5026078728, A5072223021. Sources: OpenAlex.

Their work

Papers
58 (first author 9, last author 3)
Trials
0
Grants
0
Labs led
1
Collaborators
214
Papers, trials and grants by year

2011: 4 papers · 2012: 2 papers · 2013: 3 papers · 2014: 5 papers · 2015: 6 papers · 2016: 3 papers · 2017: 2 papers · 2018: none · 2019: 5 papers · 2020: 7 papers · 2021: 8 papers · 2022: 2 papers · 2023: 1 paper · 2024: 2 papers · 2025: 5 papers · 2026: 3 papers

Papers 50 of 58

  1. Clonal evolutionary analysis reveals patterns of malignant transformation of Intraductal Papillary Mucinous Neoplasms of the pancreas. Co-author DOI 10.1038/s41467-026-69762-w↗
  2. Clinical and molecular landscape of surgically resected early onset pancreatic cancer. Co-author DOI 10.1093/bjs/znag032↗
  3. Outcomes after surgery for locally advanced pancreatic cancer compared to borderline and upfront resectable pancreatic cancer. First author DOI 10.21037/hbsn-2025-aw-868↗
  4. Routine Imaging or Symptomatic Follow-Up After Resection of Pancreatic Adenocarcinoma. Co-author DOI 10.1001/jamasurg.2024.5024↗
  5. 10-year survival after resection of pancreatic ductal adenocarcinoma with pathological re-examination of a nationwide cohort. Co-author DOI 10.1016/j.ejca.2025.116099↗
  6. Impact of social deprivation upon the preoperative pathway and early surgical outcomes after pancreatoduodenectomy for PDAC and non-PDAC periampullary cancer i… Co-author DOI 10.1016/j.hpb.2025.07.007↗
  7. An update on pancreatic cancer imaging, staging, and use of the PACT-UK radiology template pre- and post-neoadjuvant treatment. Co-author DOI 10.1093/bjr/tqae217↗
  8. Long-term Outcomes Following Resection of Adenocarcinoma Arising from Intraductal Papillary Mucinous Neoplasm (A-IPMN) Versus Pancreatic Ductal Adenocarcinoma … Co-author DOI 10.1097/sla.0000000000006272↗
  9. Evidence for molecular subtyping in pancreatic ductal adenocarcinoma: a systematic review. Co-author DOI 10.1016/j.hpb.2024.02.001↗
  10. Integrating metabolic profiling of pancreatic juice with transcriptomic analysis of pancreatic cancer tissue identifies distinct clinical subgroups. Co-author DOI 10.3389/fonc.2024.1405612↗
  11. The Impact of Molecular Subtyping on Pathological Staging of Pancreatic Cancer. Last author DOI 10.1097/sla.0000000000005050↗
  12. Genomic and Molecular Analyses Identify Molecular Subtypes of Pancreatic Cancer Recurrence. Co-author DOI 10.1053/j.gastro.2021.09.022↗
  13. Prognostic implications of microRNA-21 overexpression in pancreatic ductal adenocarcinoma: an international multicenter study of 686 patients. First author PMID 36628279↗
  14. Survival in borderline resectable and locally advanced pancreatic cancer is determined by the duration and response of neoadjuvant therapy. Co-author DOI 10.1016/j.ejso.2021.04.005↗
  15. Clinical benefit of surveillance after resection of pancreatic ductal adenocarcinoma: A systematic review and meta-analysis. Co-author DOI 10.1016/j.ejso.2021.04.031↗
  16. Impact of SARS-CoV-2 pandemic on pancreatic cancer services and treatment pathways: United Kingdom experience. Co-author DOI 10.1016/j.hpb.2021.03.003↗
  17. Reply to Comment on "The UK consensus position on the treatment of pancreatic cancer during the COVID-19 pandemic". Co-author DOI 10.1038/s41416-020-01133-8↗
  18. Modulation of pancreatic cancer cell sensitivity to FOLFIRINOX through microRNA-mediated regulation of DNA damage. Co-author DOI 10.1038/s41467-021-27099-6↗
  19. Targeting DNA Damage Response and Replication Stress in Pancreatic Cancer. Co-author DOI 10.1053/j.gastro.2020.09.043↗
  20. ROR1 and ROR2 expression in pancreatic cancer. Co-author DOI 10.1186/s12885-021-08952-9↗
  21. Surgical Management of Non-Metastatic Pancreatic Cancer in the United Kingdom: Results of a Nationwide Survey on Current Practice. Co-author DOI 10.3389/fonc.2021.791946↗
  22. HNF4A and GATA6 Loss Reveals Therapeutically Actionable Subtypes in Pancreatic Cancer. Co-author DOI 10.1016/j.celrep.2020.107625↗
  23. PRECISION-Panc: the Next Generation Therapeutic Development Platform for Pancreatic Cancer. First author DOI 10.1016/j.clon.2019.07.011↗
  24. Pancreatic Cancer: From Genome Discovery to PRECISION-Panc. First author DOI 10.1016/j.clon.2019.08.007↗
  25. Considerations for the treatment of pancreatic cancer during the COVID-19 pandemic: the UK consensus position. Co-author DOI 10.1038/s41416-020-0980-x↗
  26. Evaluation of Fluorodeoxyglucose Positron Emission Tomography Scanning in the Neoadjuvant Therapy Paradigm in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/mpa.0000000000001472↗
  27. Pancreatoduodenectomy With Arterial Resection for Locally Advanced Pancreatic Cancer of the Head: A Systematic Review. Co-author DOI 10.1097/mpa.0000000000001551↗
  28. Precision Oncology in Surgery: Patient Selection for Operable Pancreatic Cancer. Co-author DOI 10.1097/sla.0000000000003143↗
  29. Systematic review of clinical prediction models for survival after surgery for resectable pancreatic cancer. Co-author DOI 10.1002/bjs.11111↗
  30. The integrin αvβ6 drives pancreatic cancer through diverse mechanisms and represents an effective target for therapy. Co-author DOI 10.1002/path.5320↗
  31. Biomarker panel predicts survival after resection in pancreatic ductal adenocarcinoma: A multi-institutional cohort study. Co-author DOI 10.1016/j.ejso.2018.10.050↗
  32. Neoadjuvant FOLFIRINOX in Patients With Borderline Resectable Pancreatic Cancer: A Systematic Review and Patient-Level Meta-Analysis. Co-author DOI 10.1093/jnci/djz073↗
  33. Feasibility and clinical utility of endoscopic ultrasound guided biopsy of pancreatic cancer for next-generation molecular profiling. First author DOI 10.21037/cco.2019.04.06↗
  34. Hypermutation In Pancreatic Cancer. Co-author DOI 10.1053/j.gastro.2016.09.060↗
  35. The role of induction chemotherapy + chemoradiotherapy in localised pancreatic cancer: initial experience in Scotland. Co-author DOI 10.21037/jgo.2017.04.01↗
  36. CXCR2 Inhibition Profoundly Suppresses Metastases and Augments Immunotherapy in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1016/j.ccell.2016.04.014↗
  37. Genomic analyses identify molecular subtypes of pancreatic cancer. Co-author DOI 10.1038/nature16965↗
  38. Targeting inflammation in pancreatic cancer: Clinical translation. Co-author DOI 10.4251/wjgo.v8.i4.380↗
  39. microRNAs with prognostic significance in pancreatic ductal adenocarcinoma: A meta-analysis. Co-author DOI 10.1016/j.ejca.2015.04.006↗
  40. Whole genomes redefine the mutational landscape of pancreatic cancer. Co-author DOI 10.1038/nature14169↗
  41. RE: nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer: Long-Term Survival From a Phase III Trial. Last author DOI 10.1093/jnci/djv204↗
  42. Pancreatic cancer genomics: where can the science take us? First author DOI 10.1111/cge.12536↗
  43. SIRT3 & SIRT7: Potential Novel Biomarkers for Determining Outcome in Pancreatic Cancer Patients. Co-author DOI 10.1371/journal.pone.0131344↗
  44. Targeting the LOX/hypoxia axis reverses many of the features that make pancreatic cancer deadly: inhibition of LOX abrogates metastasis and enhances drug effic… Co-author DOI 10.15252/emmm.201404827↗
  45. Fascin is regulated by slug, promotes progression of pancreatic cancer in mice, and is associated with patient outcomes. Co-author DOI 10.1053/j.gastro.2014.01.046↗
  46. Targeting mTOR dependency in pancreatic cancer. Co-author DOI 10.1136/gutjnl-2013-306202↗
  47. A microRNA meta-signature for pancreatic ductal adenocarcinoma. Co-author DOI 10.1586/14737159.2014.893192↗
  48. Can we move towards personalised pancreatic cancer therapy? Co-author DOI 10.1586/17474124.2014.893820↗
  49. IP-10/CXCL10 induction in human pancreatic cancer stroma influences lymphocytes recruitment and correlates with poor survival. First author DOI 10.18632/oncotarget.2519↗
  50. The prognostic influence of resection margin clearance following pancreaticoduodenectomy for pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s11605-012-2131-z↗

Closest collaborators

The 25 strongest of 214 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Colin J. McKay · 23 shared papers, 2011–2026 · strength 1.66
  2. David Kuang-Fu Chang · 15 shared papers, 2014–2026 · strength 1.50
  3. Andrew Victor Biankin · 14 shared papers, 2014–2026 · strength 1.33
  4. Stephan B. Dreyer · 7 shared papers, 2019–2026 · strength 1.03
  5. Jaswinder Singh Samra · 8 shared papers, 2019–2023 · strength 0.81
  6. Anthony James Gill · 7 shared papers, 2019–2023 · strength 0.76
  7. Juan W. Valle · 5 shared papers, 2020–2025 · strength 0.72
  8. C. Ross Carter · 15 shared papers, 2011–2020 · strength 0.70
  9. Kjetil Søreide · 1 shared paper, 2026 · strength 0.63
  10. Jennifer P. Morton · 10 shared papers, 2012–2022 · strength 0.58
  11. Owen James Sansom · 10 shared papers, 2012–2022 · strength 0.58
  12. Anubhav Mittal · 5 shared papers, 2019–2023 · strength 0.56
  13. Alessandra Pulvirenti · 3 shared papers, 2023–2026 · strength 0.52
  14. Antonio Pea · 3 shared papers, 2023–2026 · strength 0.52
  15. Aldo Scarpa · 4 shared papers, 2019–2026 · strength 0.51
  16. Fieke E. M. Froeling · 2 shared papers, 2026 · strength 0.49
  17. Ganesh Radhakrishna · 3 shared papers, 2020–2025 · strength 0.48
  18. Karin A. Oien · 10 shared papers, 2011–2022 · strength 0.45
  19. Rita Teresa Lawlor · 3 shared papers, 2019–2026 · strength 0.42
  20. John A. G. Moir · 2 shared papers, 2021–2025 · strength 0.41
  21. Colin William Steele · 7 shared papers, 2011–2019 · strength 0.36
  22. Bas Groot Koerkamp · 3 shared papers, 2019–2025 · strength 0.35
  23. Marc G. Besselink · 3 shared papers, 2019–2025 · strength 0.35
  24. Roberto Salvia · 2 shared papers, 2023–2026 · strength 0.35
  25. Stephen John Clarke · 4 shared papers, 2019–2021 · strength 0.34

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.